Production of Biologically Derived Small Molecule Regulatory Starting Materials and/or Active Pharmaceutical Ingredients at Commercial Scale
Through these BioMaP-Consortium awards, ASPR IBMSC is partnering with the awardees listed below to develop a biological design-build-test cycle for the production of small molecule drug substances at commercial scale. This supports ASPR IBMSC’s broader long-term goal of developing and commercializing infrastructure that will be accessible to a broad community of users for the purpose of producing drug substances, creating a new manufacturing paradigm that can be competitive in the global market and to onshore drug production.
A Next-Generation Biomanufacturing Platform for Resilient, Agile, and Domestic Production of Critical Drug Substances
Project Details
Member Organization: Antheia, Inc.
Award Date: 07/15/2024
Award Ceiling: $11,089,240
Project Duration: 24 months
Solicitation Number: RPP 24-01-Small Molecule
See Antheia, Inc.’s Press Release Here
CoMPASS: Continuous BioManufacturing Process Analysis for Scaling API Synthesis
Project Details
Member Organization: Capra Biosciences, Inc.
Award Date: 07/12/2024
Award Ceiling: $7,499,615
Project Duration: 24 months
Solicitation Number: RPP 24-01-Small Molecule
See Capra Biosciences, Inc.’s Press Release Here
Leveraging Amyris’s proven R&D, scale-up, and manufacturing platform for bioproduction of small molecule drugs and intermediates
Project Details
Member Organization: Amyris, Inc.
Award Date: 09/24/2024
Award Ceiling: $12,325,400
Project Duration: 24 months
Solicitation Number: RPP 24-01-Small Molecule
